Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

Description

This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.

Interventions

• Newly obtained biopsy and Blood samples collection (Procedure)
  For each patient: * Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling * Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient. Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first. All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report.

Eligibility criteria

Conditions

Locations

• Centre Hospitalier de la Côte Basque — Bayonne, France
• Clinique Tivoli-Ducos — Bordeaux, France
• Institut Bergonie — Bordeaux, France
• Polyclinique Bordeaux Nord Aquitaine — Bordeaux, France
• Centre Hospitalier de Pau — Pau, France
• Clinique Marzet — Pau, France
• Centre Eugène Marquis — Rennes, France